MedTrace Logo

Performance of Novel Simplified Score for Chronic Hepatitis B Treatment Eligibility in Thailand

NCT05295914 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-04-04

No results posted yet for this study

Summary

International and national guideline for chronic hepatitis B (HBV) infection treatment recommend initiated antiviral in high HBV viral loads patients with significant liver inflammation and significant liver fibrosis. In Thailand, HBV viral loads and liver elastography are limited available in seconds to tertiary care hospital.

Recently, many of simplified scoring system (TREAT-B score, WHO (World Health Organization)-simplified score and REACH-B score) were developed for assessment of antiviral initiation.

This study aim to evaluate the performance of simplified score for chronic HBV treatment compare to Thailand and international standard guideline.

Conditions

Interventions

DIAGNOSTIC_TEST

TREAT-B score

TREAT-B score: ALT(alanine transferase), HBeAg REACH-B score: sex, ALT, HBV viral load, age WHO-simplified score: ALT, cirrhosis

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Watcharasak Chotiyaputta, Assoc prof · Mahidol University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-10
Primary Completion
2022-05-30
Completion
2022-05-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05295914 on ClinicalTrials.gov